What is Evox Therapeutics?
Founded in 2016, Evox Therapeutics is a biotechnology enterprise headquartered in Oxford, England, specializing in the development of exosome-based therapeutics. The company utilizes a sophisticated platform to engineer exosomes—naturally occurring extracellular vesicles—to deliver a wide range of therapeutic payloads, including proteins, nucleic acids, and small molecules. This approach offers a distinct advantage in treating rare and severe conditions, as exosomes can potentially bypass biological barriers that traditional drug delivery systems struggle to penetrate. By focusing on the intersection of synthetic biology and drug delivery, Evox Therapeutics has established a robust intellectual property portfolio and a market-leading position in the emerging field of vesicle-based medicine.
How much funding has Evox Therapeutics raised?
Evox Therapeutics has raised a total of $142.7M across 3 funding rounds:
Grant
$1.1M
Series B
$46.2M
Series C
$95.4M
Grant (2019): $1.1M with participation from Innovate UK
Series B (2020): $46.2M led by Redmile Group , LLC, Borealis Ventures, Oxford University, Panacea Healthcare Venture, Oxford Sciences Innovation, Google Ventures, and Cowen Healthcare Investments
Series C (2021): $95.4M supported by GV, OrbiMed, Redmile Group, Oxford Sciences Innovation, Invus, and Cowen Healthcare Investments
Key Investors in Evox Therapeutics
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
Redmile Group
Redmile Group LLC is a private equity and venture capital firm that provides strategic financial backing to companies within the healthcare and life sciences industries.
What's next for Evox Therapeutics?
With the successful closure of its latest financing, Evox Therapeutics is well-positioned to advance its lead candidates through critical clinical milestones. The strategic deployment of this capital will likely focus on expanding manufacturing infrastructure, enhancing the precision of its exosome-loading technology, and broadening its therapeutic pipeline. As the company matures, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities to facilitate commercialization and global distribution. The continued support from top-tier venture capital firms suggests a clear path toward long-term value creation and potential leadership in the next generation of precision medicine.
See full Evox Therapeutics company page
